Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)

NCT02506179 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02506179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02506179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
August 18, 2015
Completion date
February 10, 2020
Enrollment
100 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis